Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Y. Minoshima · SciRah

Researcher profile · Semantic Scholar

Y. Minoshima

Share profile

Y. Minoshima — researcher profile on SciRah

h-index: 21
Works: 57
Citations: 2,996

Most-cited papers

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
S. Knutson, S. Kawano, Y. Minoshima, N. Warholic +22 more
2014Molecular Cancer Therapeutics500 citations
Semantic Scholar
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
O. Tohyama, J. Matsui, Kotaro Kodama, N. Hata-Sugi +5 more
2014Journal of Thyroid Research436 citations Open access
Semantic Scholar
Selective degradation of splicing factor CAPERα by anticancer sulfonamides.
Taisuke Uehara, Y. Minoshima, K. Sagane, N. Sugi +12 more
2017Nature Chemical Biology336 citations
Semantic Scholar
Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis.
Y. Minoshima, Toshiyuki Kawashima, K. Hirose, Y. Tonozuka +12 more
2003Developmental Cell319 citations Open access
Semantic Scholar
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
M. Matsuki, Taisuke Hoshi, Yuji Yamamoto, M. Ikemori-Kawada +3 more
2018Cancer Medicine248 citations Open access
Semantic Scholar
Biological validation that SF3b is a target of the antitumor macrolide pladienolide
A. Yokoi, Y. Kotake, Kentaro Takahashi, T. Kadowaki +7 more
2011The FEBS Journal164 citations Open access
Semantic Scholar
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
J. Campbell, K. Kuntz, S. Knutson, N. Warholic +15 more
2015ACS Medicinal Chemistry Letters126 citations Open access
Semantic Scholar
Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors
Toshiyuki Kawashima, Ying Bao, Yasushi Nomura, Y. Moon +9 more
2006Journal of Cell Biology108 citations Open access
Semantic Scholar
A Rac GTPase-Activating Protein, MgcRacGAP, Is a Nuclear Localizing Signal-Containing Nuclear Chaperone in the Activation of STAT Transcription Factors
Toshiyuki Kawashima, Ying Bao, Y. Minoshima, Yasushi Nomura +12 more
2009Molecular and Cellular Biology83 citations Open access
Semantic Scholar
The Constitutive Centromere Component CENP-50 Is Required for Recovery from Spindle Damage
Y. Minoshima, T. Hori, M. Okada, H. Kimura +6 more
2005Molecular and Cellular Biology82 citations Open access
Semantic Scholar
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
R. Finn, M. Kudo, A. Cheng, L. Wyrwicz +17 more
2021Clinical Cancer Research65 citations Open access
Semantic Scholar
STAT5 Induces Macrophage Differentiation of M1 Leukemia Cells Through Activation of IL-6 Production Mediated by NF-κB p651
Toshiyuki Kawashima, K. Murata, S. Akira, Y. Tonozuka +8 more
2001Journal of Immunology65 citations Open access
Semantic Scholar
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
S. Kawano, A. Grassian, M. Tsuda, S. Knutson +13 more
2016PLoS ONE63 citations Open access
Semantic Scholar
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
Kenji Ichikawa, Saori Watanabe Miyano, Y. Minoshima, J. Matsui +1 more
2020Scientific Reports52 citations Open access
Semantic Scholar
A GTPase-activating protein binds STAT3 and is required for IL-6-induced STAT3 activation and for differentiation of a leukemic cell line.
Y. Tonozuka, Y. Minoshima, Ying Bao, Y. Moon +6 more
2004Blood42 citations
Semantic Scholar
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima +18 more
2016Molecular Cancer Therapeutics39 citations Open access
Semantic Scholar
Role of MgcRacGAP/Cyk4 as a regulator of the small GTPase Rho family in cytokinesis and cell differentiation.
Toshio Kitamura, Toshiyuki Kawashima, Y. Minoshima, Y. Tonozuka +2 more
2001Cell Structure and Function31 citations Open access
Semantic Scholar
Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Y. Narita, Kiyoshi Okamoto, M. Kawada, Kazuma Takase +5 more
2014Molecular Cancer Therapeutics29 citations Open access
Semantic Scholar
High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab.
Chung-Han Lee, R. DiNatale, Diego Chowell, C. Krishna +22 more
2021Molecular Cancer Research26 citations Open access
Semantic Scholar
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R. Motzer, C. Porta, M. Eto, T. Hutson +16 more
2024Annals of Oncology25 citations Open access
Semantic Scholar
The spatial and temporal expression of delta-like protein 1 in the rat pituitary gland during development
T. Nakakura, M. Sato, Masakazu Suzuki, O. Hatano +4 more
2008Histochemistry and Cell Biology22 citations
Semantic Scholar
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
V. Makker, M. Taylor, C. Aghajanian, A. Cohn +13 more
2024Journal for ImmunoTherapy of Cancer19 citations Open access
Semantic Scholar
LBA30Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
R. Finn, M. Kudo, A. Cheng, L. Wyrwicz +16 more
201716 citations Open access
Semantic Scholar
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee, R. Motzer, H. Glen, M. Michaelson +8 more
2020British Journal of Cancer15 citations Open access
Semantic Scholar
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
Yuki Niwa, Keito Adachi, Kimiyo Tabata, Ryoga Ishida +7 more
2023Molecular Cancer Therapeutics14 citations Open access
Semantic Scholar
Molecular cloning, expression analysis, promoter characterization, and chromosomal localization of the bovine PREF1 gene.
Y. Minoshima, Y. Taniguchi, K. Tanaka, Takahisa Yamada +1 more
2001Animal Genetics10 citations
Semantic Scholar
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
R. Motzer, C. Porta, Masatoshi Eto, T. Hutson +15 more
2024Journal of Clinical Oncology9 citations
Semantic Scholar
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
J. Eng, Yu Kato, Y. Adachi, B. Swaminathan +25 more
2024Cancer Research Communications7 citations Open access
Semantic Scholar
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.
V. Makker, A. Cohn, M. Taylor, Y. Minoshima +9 more
20186 citations
Semantic Scholar
Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice
H. Keilhack, A. Yokoi, S. Knutson, T. Wigle +17 more
20126 citations
Semantic Scholar
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
S. Kitano, Y. Fujiwara, T. Shimizu, S. Iwasa +11 more
2022Cancer Chemotherapy and Pharmacology5 citations
Semantic Scholar
Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.
Chung-Han Lee, R. DiNatale, Diego Chowell, C. Krishna +15 more
20204 citations
Semantic Scholar
Abstract 3614: Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition
J. Matsui, Y. Minoshima, A. Tsuruoka, Y. Funahashi
20104 citations
Semantic Scholar
Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146.
Chung-Han Lee, D. Rasco, Arpit Rao, M. Taylor +16 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
A. Zhu, J. Llovet, Masahiro Kobayashi, M. Ikeda +15 more
20213 citations
Semantic Scholar
719P Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
C-H. Lee, Y. Adachi, H. Ikezawa, S.-D. Li +7 more
20203 citations Open access
Semantic Scholar
Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma.
C-H. Lee, R. Motzer, H. Glen, M. Michaelson +8 more
2018Annals of Oncology3 citations Open access
Semantic Scholar
Role of MgcRacGAP / Cyk 4 as a Regulator of the Small GTPase Rho Family in Cytokinesis and Cell Differentiation
T. Kitamura, Toshiyuki Kawashima, Y. Minoshima, Y. Tonozuka +2 more
20023 citations
Semantic Scholar
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
S. Kawano, A. Grassian, M. Tsuda, S. Knutson +13 more
2017PLoS ONE2 citations Open access
Semantic Scholar
Abstract 770: E7090: A potent and selective FGFR inhibitor with activity in multiple FGFR-driven cancer models with distinct mechanisms of activation
S. W. Miyano, Yuji Yamamoto, Kotaro Kodama, S. Funasaka +18 more
20152 citations
Semantic Scholar
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.
T. R. Jeffry Evans, Masatoshi Kudo, A. Cheng, L. Wyrwicz +15 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
V. Makker, M. Taylor, C. Aghajanian, A. Cohn +16 more
2021Annals of Oncology1 citations Open access
Semantic Scholar
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee, R. Motzer, H. Glen, M. Michaelson +8 more
2020British Journal of Cancer1 citations Open access
Semantic Scholar
Abstract 1371: Systems biology analysis to identify biomarkers for lenvatinib in the preclinical cancer cell line panels
Z. Dezső, M. Ino, Y. Minoshima, O. Tohyama +4 more
20151 citations
Semantic Scholar
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
J. Eng, Yu Kato, Y. Adachi, B. Swaminathan +25 more
2025Cancer Research Communications0 citations
Semantic Scholar
Abstract 1485: E7011, a novel anti-angiogenesis inhibitor targeting Notch4 receptor signal pathway
Y. Adachi, Yoshimasa Sakamoto, Youya Nakazawa, Sho Tachino +19 more
2020Tumor Biology0 citations
Semantic Scholar
Abstract 196: Antitumor activity of lenvatinib against acquired resistance tumor to anti-VEGF therapy in mouse syngeneic tumor models
Kenji Ichikawa, S. W. Miyano, Y. Minoshima, J. Matsui +1 more
2019Tumor Biology0 citations Open access
Semantic Scholar
Identification of novel molecular glue that induces selective degradation of splicing factor CAPER-alpha via CUL4-DCAF15 ubiquitin ligase
Taisuke Uehara, Y. Minoshima, K. Sagane, N. Sugi +11 more
20190 citations
Semantic Scholar
FGFR-1 in complex with ligand lenvatinib
M. Matsuki, Taisuke Hoshi, Yuji Yamamoto, M. Ikemori-Kawada +3 more
20180 citations
Semantic Scholar
Abstract B095: Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models
Taisuke Hoshi, M. Matsuki, Yuji Yamamoto, Y. Minoshima +2 more
20180 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Funahashi×22
Invite
Y. Funahashi — researcher profile on SciRah
J. Matsui×18
Invite
J. Matsui — researcher profile on SciRah
Masao Iwata×8
Invite
Masao Iwata — researcher profile on SciRah
Toshiyuki Kawashima×8
Invite
Toshiyuki Kawashima — researcher profile on SciRah

×8

Invite

C. Dutcus — researcher profile on SciRah

Invite

R. Motzer — researcher profile on SciRah

Invite

T. Nosaka — researcher profile on SciRah

Invite

T. Kitamura — researcher profile on SciRah

Invite

P. Sachdev — researcher profile on SciRah

Invite

A. Yokoi — researcher profile on SciRah

Invite

N. Sugi — researcher profile on SciRah

Invite

Y. Tonozuka — researcher profile on SciRah